Name: Hormone Refractory Prostate Cancer (HRPCA) Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH3383
Price: 4350 USD
Availability: InStock

Hormone Refractory Prostate Cancer Market Analysis, Size 2023-2030

Hormone Refractory Prostate Cancer (HRPCA) Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Hormone Refractory Prostate Cancer (HRPCA) Market is segmented By Treatment type (Chemotherapy (Cytotoxic agents), Hormone therapy (Anti-androgen agents), Surgery, Radiation therapy, Others), By End-users (Hospitals, Surgical Centers, Ambulatory Care Units, Others), By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global Hormone Refractory Prostate Cancer Market is expected to grow at a high&nbsp;CAGR during the forecasting period (2023-2030).&nbsp;
</blockquote>

Hormone refractory prostate cancer is also called as Castrate-Resistant Prostate Cancer (CRPC)occurs when hormone therapy fails to stop the growth of prostate cancer for any longer. Hormone refractory prostate cancer may occur a few months or even years after hormone therapy has been started. Most prostate cancers are found during screening with a digital rectal exam or prostate-specific antigen blood test. Initially, prostate cancers usually don&#39;t show any symptoms, but sometimes symptoms can be seen in advancing cancer stages. If Hormone Refractory Prostate Cancer is suspected based on the outcomes of screening tests or symptoms, tests are needed to confirm the diagnosis. A definite diagnosis of prostate cancer can be made with a prostate biopsy. When hormones fail to stop cancer&#39;s growth and spread any longer, the next step is usually chemotherapy drugs. As patients advance into stage T3 and stage T4 of prostate cancer, they have a local extension through the lymph nodes and seminal vesicles. It has chances that cancer could metastasize to the bones. The more quickly prostate cancer grows, the more likely the diseases will respond to chemotherapy treatment.

<h2>Market Dynamics</h2>

The global Hormone Refractory Prostate Cancer (HRPCA) market growth is driven by the growing prevalence of Prostate cancers, Emerging strong pipeline drugs, Growing patient awareness, Availability of new prostate cancer treatments are among the key factors driving the market growth.&nbsp;

An emerging strong pipeline of drugs is increasing the demand for the global Hormone Refractory Prostate Cancer (HRPCA) market during the forecast period.

Janssen Pharmaceuticals developing niraparib for treating castration-resistant prostate cancer in combination with abiraterone acetate and Prednisone is under Phase III trials in U.S and E.U.

Bayer undergoing a Phase I trial to study is the safety and toxicity of Fractionated Docetaxel and Radium 223 in Castration-Resistant Prostate Cancer (CRPC) patients.

Increasing the Prevalence of Prostate Cancers is expected to drive the global Hormone Refractory Prostate Cancer (HRPCA) market during the forecast period.

According to the National Cancer Institute NIH, Prostate cancer is the fifth leading cause of cancer death in the United States. The rate of new prostate cancer cases was 109.8 per 100,000 men per year. In 2017, an estimated 3,170,339 men were living with prostate cancer in the United States. In 2020, it was estimated that there would be 191,930 new cases of prostate cancer.&nbsp; According to WHO, Prostate cancer cases estimated in 2020 were 1.41 million. These factors are driving the growth of the market in the forecast period.

High treatment costs are likely to hinder the global Hormone Refractory Prostate Cancer (HRPCA) market growth.

According to the American Cancer Society, on average, prostate cancer costs about $4,300 initially and about $9,100 over five years, and it costs about $15,000 initially and $19,000 over five years for surgery. Hormone therapy with radiation costs about $17,500 initially and $25,000 total over five years. For patients with advanced prostate cancer, costs can reach $100,000 or more.

<h2>COVID-19 Impact Analysis</h2>

The COVID-19 pandemic has negatively impacted healthcare systems globally and on the vulvar Cancer market. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the Ongoing clinical trials too. However, the situation is expected to improve gradually.

<h2>Segment Analysis</h2>

Based on Treatment Type, the global Hormone Refractory Prostate Cancer (HRPCA) market is segmented into Chemotherapy (Cytotoxic agents), Hormone therapy (Anti-androgen agents), Radiation therapy, Surgery and Others

Prostate cancer chemotherapy treatment is almost always a salvage therapy for advanced prostate cancers. When treatments like cryotherapy or prostate surgery fail, the next step is either another type of treatment or prostate cancer hormone therapy. Once the patient starts hormone therapy, the disease can be effectively controlled and even stops for a while. Hormone therapy will eventually fail, however, and prostate cancer will continue to grow and spread. This is called hormone-refractory prostate cancer and is commonly seen during the advanced stages of prostate cancer. Then the next step is usually chemotherapy.

The chemotherapy (Cytotoxic agents) segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)&nbsp;&nbsp;&nbsp;

Chemotherapy (chemo) uses anti-cancer drugs injected into a vein or given by mouth. These drugs travel through the bloodstream to reach cancer cells in most parts of the body. These drugs have been in the market for some time, and the growth of this segment is imminent because of the availability and cost-effective nature of these drugs. Some of the chemo drugs used to treat HRPCA include Docetaxel (Taxotere), Cabazitaxel (Jevtana), Mitoxantrone (Novantrone), Estramustine (Emcyt), Vinblastine, Carboplatin, Etoposide, Paclitaxel.

For instance, in Nov 2020, Astellas Pharma Inc. got approval under the licensor with Pfizer of MDV3100 (now Xtandi) to treat HRPCA. For instance, in Nov 2020, Astellas Pharma Inc. got approval under the licensor with Pfizer of MDV3100 (now Xtandi) to treat HRPCA.

Based on End-User, the global Hormone Refractory Prostate Cancer (HRPCA)&nbsp; market is segmented into Hospitals, Cancer Research centres, clinics, others.

Due to the growing patient population, the hospital&#39;s segment held the largest market share. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also, the medications can only be administrated intravenously and surgery is done under the supervision of medical practioners at these locations.

<h2>Geographical Analysis</h2>

North America served the largest share of the market due to the increasing prevalence of Metastatic prostate cancer cases. According to the American Cancer Society, the prostate cancer prevalence in 2019 estimated was 174,650 prostate cancers and in the United States for 2021 new cases are about 248,530. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced diagnostic tools, and many companies are developing oncology products.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to the increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Suzhou Kintor Pharmaceutical Inc is ongoing An Extended/Phase 2, Study to Evaluate the Safety and Tolerability of GT0918 in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide.

<h2>Competitive Landscape&nbsp;</h2>

The global Hormone Refractory Prostate Cancer (HRPCA) market is quite competitive with some key competitors like AbbVie Inc, Acceleron Pharma, Inc, AB Science SA, AstraZeneca Plc, Astellas Pharma Inc, Sanofi S.A, Bayer AG, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Johnson and Johnson and others. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, According to clinicaltrials.gov; Merck Sharp &amp; Dohme Corp-A Phase 2 Study of a Checkpoint Inhibitor in Men with Progressive Metastatic Castrate Resistant Prostate Cancer.

Johnson &amp; Johnson Services Inc

Company Overview:&nbsp;Johnson &amp; Johnson Services Inc is an American multinational company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in baby care, oral care, beauty, over-the-counter pharmaceutical, women&#39;s health, and wound care markets and the Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular &amp; neurovascular and eye health fields. Robert Wood Johnson founded the company I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ. On October 24, 1961, the company Janssen was acquired by Johnson &amp; Johnson. In 2011, Johnson &amp; Johnson subsidiary Centocor became Janssen Biotech, part of Janssen Pharmaceuticals. Also, in 2011, Johnson &amp; Johnson acquired Crucell and assigned it to Janssen. The acquisition of Crucell provided Janssen with a disease prevention arm. By 2014, Crucell was renamed Janssen Vaccines.

&nbsp;

Product Portfolio: The Company&rsquo;s portfolio comprised of include immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular &amp; metabolic diseases in the Pharmaceutical segment.

Key developments:

Janssen Research &amp; Development, LLCA multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Subjects with Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC).

Why Purchase the Report?

<ul>
	<li>Visualize the composition of the Hormone Refractory Prostate Cancer (HRPCA) Market segmentation by Treatment type, End-users, and region highlighting the key commercial assets and players.</li>
	<li>Identify commercial opportunities in Hormone Refractory Prostate Cancer (HRPCA) Market by analyzing trends and co-development deals.&nbsp;</li>
	<li>Excel data sheet with thousands of data points of Hormone Refractory Prostate Cancer (HRPCA) Market - level 4/5 segmentation.</li>
	<li>PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.&nbsp;</li>
	<li>Product mapping in excel for the key product of all major market players</li>
</ul>

The global Hormone Refractory Prostate Cancer (HRPCA) Market report would provide access to an approx. 53 market data table, 45 figures and 180 pages.&nbsp;

Target Audience

<ul>
	<li>Service Providers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Education &amp; Research Institutes</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
	<li>Manufacturers</li>
</ul>

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/chemotherapy-induced-peripheral-neuropathy-treatment-market">Chemotherapy Induced Peripheral Neuropathy Treatment Market</a>

<a href="https://www.datamintelligence.com/research-report/hormone-replacement-therapy-market">Hormone Replacement Therapy (HRT) Market</a>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Market Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Market snippet by Treatment Type</li>
		<li>Market Snippet by End-users</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Emerging strong pipeline drugs</li>
				<li>Increasing prevalence of Prostate cancer cases</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>High cost of treatments</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&#39;s Five Forces Analysis&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
		<li>Reimbursement Analysis</li>
		<li>Unmet Needs</li>
	</ol>
	</li>
	<li>COVID-19 Analysis
	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Treatment type</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type</li>
		<li>Market Attractiveness Index, By Treatment type
		<ol>
			<li>Chemotherapy (Cytotoxic agents) *
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Hormone therapy (Anti-androgen agents)</li>
			<li>Surgery</li>
			<li>Radiation therapy</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End-users</h3>

	<ol>
		<li>Introduction</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment</li>
		<li>Market Attractiveness Index, By End-users Segment
		<ol>
			<li>Hospitals*
			<ol>
				<li>Introduction</li>
				<li>Market Size Analysis, and Y-o-Y Growth Analysis (%)</li>
			</ol>
			</li>
			<li>Surgical Centers</li>
			<li>Ambulatory Care Units&nbsp;</li>
			<li>Others</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction&nbsp;</li>
		<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region</li>
		<li>Market Attractiveness Index, By Region</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>Johnson &amp; Johnson Services Inc*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>AbbVie Inc,&nbsp;</li>
		<li>Acceleron Pharma, Inc,&nbsp;</li>
		<li>AB Science SA,&nbsp;</li>
		<li>AstraZeneca Plc,&nbsp;</li>
		<li>Astellas Pharma Inc,&nbsp;</li>
		<li>Sanofi S.A,&nbsp;</li>
		<li>Bayer AG,&nbsp;</li>
		<li>Boston Biomedical, Inc,&nbsp;</li>
		<li>Bristol-Myers Squibb Company(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Premium Insights</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">DataM Intelligence&nbsp;</h3>

	<ol>
		<li>&nbsp;Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

List of Tables

Table 1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2021,2025 &amp; 2029 ($ Million)

Table 2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2021,2025 &amp; 2029 ($ Million)

Table 3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2021,2025 &amp; 2029 ($ Million)

Table 5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 6 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2021,2025 &amp; 2029 ($ Million)

Table 7 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2018-2029 ($ Million)

Table 8 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 9 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Region, 2018-2029 ($ Million)

Table 10 North America Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 11 North America Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2018-2029 ($ Million)

Table 12 North America Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Country, 2018-2029 ($ Million)

Table 13 South America Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 14 South America Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2018-2029 ($ Million)

Table 15 South America Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Country, 2018-2029 ($ Million)

Table 16 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 17 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2018-2029 ($ Million)

Table 18 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Country, 2018-2029 ($ Million)

Table 19 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 20 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2018-2029 ($ Million)

Table 21 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Country, 2018-2029 ($ Million)

Table 22 Middle East &amp; Africa Hormone Refractory Prostate Cancer (HRPCA) Market Value, By Treatment Type, 2018-2029 ($ Million)

Table 23 Middle East &amp; Africa Hormone Refractory Prostate Cancer (HRPCA) Market Value, By End-Users, 2018-2029 ($ Million)

Table 24 Johnson &amp; Johnson Services Inc: Overview

Table 25 Johnson &amp; Johnson Services Inc: Product Portfolio

Table 26 Johnson &amp; Johnson Services Inc: Key Developments

Table 27 AbbVie Inc: Overview

Table 28 AbbVie Inc: Product Portfolio

Table 29 AbbVie Inc: Key Developments

Table 30 Acceleron Pharma, Inc: Overview

Table 31 Acceleron Pharma, Inc: Product Portfolio

Table 32 Acceleron Pharma, Inc: Key Developments

Table 33 AB Science SA: Overview

Table 34 AB Science SA: Product Portfolio

Table 35 AB Science SA: Key Developments

Table 36 AstraZeneca Plc: Overview

Table 37 AstraZeneca Plc: Product Portfolio

Table 38 AstraZeneca Plc: Key Developments

Table 39 Astellas Pharma Inc: Overview

Table 40 Astellas Pharma Inc: Product Portfolio

Table 41 Astellas Pharma Inc: Key Developments

Table 42 Boston Biomedical, Inc: Overview

Table 43 Boston Biomedical, Inc: Product Portfolio

Table 44 Boston Biomedical, Inc: Key Developments

Table 45 Bristol-Myers Squibb Company: Overview

Table 46 Bristol-Myers Squibb Company: Product Portfolio

Table 47 Bristol-Myers Squibb Company: Key Developments

Table 48 Sanofi S.A: Overview

Table 49 Sanofi S.A: Product Portfolio

Table 50 Sanofi S.A: Key Developments

Table 51 Bayer AG: Overview

Table 52 Bayer AG: Product Portfolio

Table 53 Bayer AG: Key Developments

List of Figures

Figure 1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Region, 2021 &amp; 2029 (%)

Figure 4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Y-o-Y Growth, By Treatment Type, 2021-2029 (%)

Figure 6 Chemotherapy (Cytotoxic agents): Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 7 Hormone therapy (Anti-androgens agents): Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 8 Radiation therapy: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 9 Surgery: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 10 Others: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 11 Global Hormone Refractory Prostate Cancer (HRPCA) Market Y-o-Y Growth, By End-Users, 2021-2029 (%)

Figure 12 Hospitals: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 13 Surgical centers: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 14 Ambulatory Care Units: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 15 Others: Global Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 16 Global Hormone Refractory Prostate Cancer (HRPCA) Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 17 North America Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 18 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 19 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 20 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 21 South America Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 22 South America Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 23 South America Hormone Refractory Prostate Cancer (HRPCA) Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 24 South America Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 25 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 26 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 27 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 28 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 29 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 30 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 31 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 32 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Country, 2021 &amp; 2029 (%)

Figure 33 Middle East &amp; Africa Hormone Refractory Prostate Cancer (HRPCA) Market Value, 2018-2029 ($ Million)

Figure 34 Middle East &amp; Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share, By Treatment Type, 2021 &amp; 2029 (%)

Figure 35 Middle East &amp; Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share, By End-Users, 2021 &amp; 2029 (%)

Figure 36 Johnson &amp; Johnson Services Inc: Financials

Figure 37 AbbVie Inc: Financials

Figure 38 Acceleron Pharma, Inc: Financials

Figure 39 AB Science SA: Financials

Figure 40 AstraZeneca Plc: Financials

Figure 41 Astellas Pharma Inc: Financials

Figure 42 Boston Biomedical, Inc: Financials

Figure 43 Bristol-Myers Squibb Company: Financials

Figure 44 Sanofi S.A: Financials

Figure 45 Bayer AG: Financials